Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018373 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 20, Issue 1, pp. 110-119

Field-Weighted Citation Impact: 16.18